Hua Medicine(HK:2552)
HK$2.18-0.03 (-1.14%)
HK:2552
Hua Medicine financials statements
HK$2.18
At close:-0.03 (-1.14%)
Want to see HK:2552 full AI Analyst Report?
Hua Medicine (2552) Ratios
4 Followers
Hua Medicine Ratios
HK:2552's free cash flow for Q2 2026 was ¥-66.58M. For the 2026 fiscal year, HK:2552's free cash flow was decreased by ¥-3.76M and operating cash flow was ¥-62.82M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.17 | 4.05 | 6.24 | 4.99 | 6.59 |
| Quick Ratio | 5.59 | 3.66 | 5.97 | 4.98 | 6.59 |
| Cash Ratio | 5.19 | 3.45 | 5.80 | 2.60 | 6.32 |
| Solvency Ratio | 2.40 | -0.14 | -0.11 | -0.20 | -0.70 |
| Operating Cash Flow Ratio | -0.25 | -1.27 | 3.53 | -1.22 | -2.55 |
| Short-Term Operating Cash Flow Coverage | -1.70 | -4.25 | 51.73 | -6.78 | 0.00 |
| Net Current Asset Value | ¥ 833.50M | ¥ -326.26M | ¥ -51.74M | ¥ 98.34M | ¥ 251.38M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.21 | 0.20 | 0.10 | 0.09 | 0.08 |
| Debt-to-Equity Ratio | 0.30 | -2.22 | 1.66 | 0.35 | 0.16 |
| Debt-to-Capital Ratio | 0.23 | 1.82 | 0.62 | 0.26 | 0.14 |
| Long-Term Debt-to-Capital Ratio | 0.18 | 42.43 | 0.51 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.46 | -11.27 | 17.06 | 4.01 | 2.01 |
| Debt Service Coverage Ratio | -2.82 | -3.23 | -6.66 | -4.47 | -78.40 |
| Interest Coverage Ratio | -17.79 | -40.96 | -36.56 | -72.84 | -81.14 |
| Debt to Market Cap | 0.09 | 0.18 | 0.07 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.31 | 0.31 | 0.18 | 0.10 | 0.08 |
| Net Debt to EBITDA | 7.28 | 2.43 | 7.74 | 2.34 | 1.95 |
| Profitability Margins | |||||
| Gross Profit Margin | 56.87% | 48.74% | 48.78% | 43.69% | 0.00% |
| EBIT Margin | -29.39% | -140.80% | -265.41% | -1135.52% | 0.00% |
| EBITDA Margin | -22.63% | -134.96% | -218.10% | -954.96% | 0.00% |
| Operating Profit Margin | -29.39% | -137.81% | -377.36% | -1517.80% | 0.00% |
| Pretax Profit Margin | 224.44% | -97.75% | -275.73% | -1156.36% | 0.00% |
| Net Profit Margin | 224.44% | -97.75% | -275.73% | -1157.83% | 0.00% |
| Continuous Operations Profit Margin | 224.44% | -97.75% | -275.73% | -1156.36% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.13% | 101.60% |
| EBT Per EBIT | -763.62% | 70.93% | 73.07% | 76.19% | 101.63% |
| Return on Assets (ROA) | 73.30% | -16.38% | -12.24% | -18.17% | -36.63% |
| Return on Equity (ROE) | 107.04% | 184.65% | -208.83% | -72.88% | -73.49% |
| Return on Capital Employed (ROCE) | -11.20% | -29.46% | -19.62% | -28.63% | -40.23% |
| Return on Invested Capital (ROIC) | -10.78% | -26.87% | -19.08% | -27.02% | -39.57% |
| Return on Tangible Assets | 74.44% | -16.66% | -12.45% | -18.70% | -37.00% |
| Earnings Yield | 39.43% | -18.59% | -12.11% | -6.38% | -11.20% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.92 | 6.57 | 78.25 | 1.36 | 0.00 |
| Payables Turnover | 2.54 | 2.06 | 0.76 | 0.47 | 0.00 |
| Inventory Turnover | 1.70 | 1.04 | 0.58 | 5.17 | 0.00 |
| Fixed Asset Turnover | 4.36 | 1.97 | 0.67 | 0.13 | 0.00 |
| Asset Turnover | 0.33 | 0.17 | 0.04 | 0.02 | 0.00 |
| Working Capital Turnover Ratio | 0.46 | 0.22 | 0.07 | 0.03 | 0.00 |
| Cash Conversion Cycle | 132.52 | 230.83 | 155.67 | -433.83 | 0.00 |
| Days of Sales Outstanding | 61.64 | 55.59 | 4.66 | 268.44 | 0.00 |
| Days of Inventory Outstanding | 214.86 | 352.56 | 631.33 | 70.53 | 0.00 |
| Days of Payables Outstanding | 143.98 | 177.32 | 480.33 | 772.80 | 0.00 |
| Operating Cycle | 276.50 | 408.15 | 635.99 | 338.97 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.05 | -0.43 | 0.91 | -0.24 | -0.29 |
| Free Cash Flow Per Share | -0.06 | -0.43 | 0.90 | -0.27 | -0.35 |
| Dividend Paid and CapEx Coverage Ratio | -6.91 | -108.28 | 90.36 | -8.38 | -4.08 |
| Capital Expenditure Coverage Ratio | -6.91 | -108.28 | 90.36 | -8.38 | -4.08 |
| Operating Cash Flow Coverage Ratio | -0.17 | -1.39 | 5.30 | -2.36 | -3.82 |
| Operating Cash Flow to Sales Ratio | -0.11 | -1.63 | 11.61 | -13.08 | 0.00 |
| Free Cash Flow Yield | -2.18% | -31.35% | 50.43% | -8.07% | -11.50% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 2.54 | -5.38 | -8.26 | -15.67 | -8.93 |
| Price-to-Sales (P/S) Ratio | 5.69 | 5.26 | 22.77 | 181.41 | 0.00 |
| Price-to-Book (P/B) Ratio | 2.71 | -9.93 | 17.24 | 11.42 | 6.56 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -45.79 | -3.19 | 1.98 | -12.39 | -8.70 |
| Price-to-Operating Cash Flow Ratio | -52.42 | -3.22 | 1.96 | -13.87 | -10.83 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | -0.39 | -1.73 | 0.41 | 0.52 |
| Enterprise Value Multiple | -17.88 | -1.47 | -2.70 | -16.66 | -7.59 |
| Enterprise Value | 1.94B | 506.15M | 450.99M | 2.80B | 2.35B |
| EV to EBITDA | -17.88 | -1.47 | -2.70 | -16.66 | -7.59 |
| EV to Sales | 4.05 | 1.98 | 5.89 | 159.07 | 0.00 |
| EV to Free Cash Flow | -32.54 | -1.20 | 0.51 | -10.87 | -6.92 |
| EV to Operating Cash Flow | -37.25 | -1.21 | 0.51 | -12.17 | -8.61 |
| Tangible Book Value Per Share | 1.00 | -0.16 | 0.07 | 0.26 | 0.46 |
| Shareholders’ Equity Per Share | 1.02 | -0.14 | 0.10 | 0.29 | 0.47 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.49 | 0.26 | 0.08 | 0.02 | 0.00 |
| Net Income Per Share | 1.09 | -0.25 | -0.22 | -0.21 | -0.35 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.02 |
| Interest Burden | -7.64 | 0.69 | 1.04 | 1.02 | 1.01 |
| Research & Development to Revenue | 0.29 | 0.84 | 2.24 | 7.36 | 0.00 |
| SG&A to Revenue | 0.58 | 1.05 | 1.62 | 7.38 | 0.00 |
| Stock-Based Compensation to Revenue | 0.03 | 0.05 | 0.31 | 1.21 | 0.00 |
| Income Quality | -0.05 | 1.67 | -4.21 | 1.13 | 0.84 |
Currency in CNY
